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Abstract
Background: The aim of this study was to describe how diabetes complications influence the health-related
quality of life of individuals with diabetes using the individual EQ-5D dimensions and the EQ-5D index.
Methods: We mailed a questionnaire to 1,000 individuals with diabetes type 1 and 2 in Norway. The questionnaire
had questions about socio-demographic characteristics, use of health care, diabetes complications and finally the
EQ-5D descriptive system. Logistic regressions were used to explore determinants of responses in the EQ-5D
dimensions, and robust linear regression was used to explore determinants of the EQ-5D index.
Results: In multivariate analyses the strongest determinants of reduced MOBILITY were neuropathy and ischemic
heart disease. In the ANXIETY/DEPRESSION dimension of the EQ-5D, “fear of hypoglycaemia” was a strong
determinant. For those without complications, the EQ-5D index was 0.90 (type 1 diabetes) and 0.85 (type 2
diabetes). For those with complications, the EQ-5D index was 0.68 (type 1 diabetes) and 0.73 (type 2 diabetes). In
the linear regression the factors with the greatest negative impact on the EQ-5D index were ischemic heart disease
(type 1 diabetes), stroke (both diabetes types), neuropathy (both diabetes types), and fear of hypoglycaemia (type 2
diabetes).
Conclusions: The EQ-5D dimensions and the EQ-5D seem capable of capturing the consequences of diabetes-
related complications, and such complications may have substantial impact on several dimensions of health-related
quality of life (HRQoL). The strongest determinants of reduced HRQoL in people with diabetes were ischemic heart
disease, stroke and neuropathy.
Background
Diabetes is a chronic disease with serious short-term
and long-term consequences for the afflicted. The total
number of individuals with diabetes worldwide is pro-
jected to rise from about 170 million in 2000 to about
370 million in 2030 [1]. In the long term, diabetes
causes microvascular complications (e.g. retinopathy and
neuropathy) and macrovascular complications (e.g. myo-
cardial infarction, angina pectoris and stroke). In addi-
tion to diabetes-related complications, episodes of
hypoglycaemia, fear of hypoglycaemia, change in life
style and fear of long term consequences may lead to
reduced health-related quality of life (HRQoL). In fact,
individuals with diabetes have reduced HRQoL com-
pared with those without diabetes in the same age
group [2,3], and their HRQoL decreases with disease
progression and complications [4,5].
There are three main approaches to describe and mea-
sure HRQoL: Disease-specific instruments, generic instru-
ments and utility instruments. Numerous disease-specific
HRQoL measures exist for diabetes, and these score
HRQoL on ordinal scales [6-8]. Generic instruments such
as the Short Form 36 (SF-36) are also used [9]. In multi-
attribute utility instruments (MAU), such as the EQ-5D
[10], 15D [11], Health Utility index (HUI) [12,13] and SF-
6D [14], respondents indicate levels of health problems on
a number of dimensions of health. These values are trans-
lated into a zero-one scale where zero denotes death and
one perfect health. Some utility instruments allow for
negative values, meaning that some health states are con-
sidered worse than death. Preference-based methods such
as the time trade-off method (TTO) [15], standard gamble
( S G )o rt h ev i s u a la n a l o g u es c a l e( V A S )m a yb eu s e dt o
develop translation algorithms. When the HRQoL weight
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effect, expected remaining life years) the product is
denoted QALY (quality-adjusted life years) [16]. QALYs
can be calculated for different patient groups to compare
for example effectiveness of treatment, enabling health
improvements and life extensions to be captured in one
single variable.
EQ-5D [10] is a MAU instrument with five dimen-
sions (MOBILITY, SELF-CARE, USUAL ACTIVITIES,
PAIN/DISCOMFORT and ANXIETY/DEPRESSION)
and three levels on each dimension, and has previously
been used in populations with diabetes [17]. EQ-5D has
been used extensively in economic evaluation, and is
recommended for use in cost-effectiveness analyses by
institutions such as the National Institute for Clinical
Excellence (NICE) in the UK and the Health Care Insur-
ance Board in the Netherlands. Therefore, researchers
working with economic evaluation, government agencies
and the pharmaceutical industry need easy access to uti-
lity data for different types of patients.
Against this background the aim of this study was
three-fold:
￿ To use the five individual EQ-5D dimensions to
describe some aspects of HRQoL in a group of peo-
ple with diabetes.
￿ To investigate the impact of self-reported diabetes-
related complications on the EQ-5D dimension
scores.
￿ To investigate determinants of EQ-5D index in
order to offer researchers utility data for individuals
with diabetes.
Methods
The data in this study stem from a Norwegian survey of
people with diabetes in 2006. A questionnaire was devel-
oped and piloted among health care professionals,
including physicians with diabetes expertise and the
county leaders of the Norwegian Diabetes Association
(NDA). The latter group served as representatives of the
target group. The study was approved by the Regional
Ethics Committee and the Norwegian Data Inspectorate.
The seven-page questionnaire captured background
variables such as age, gender, location, income in Nor-
wegian Kroner (NOK), smoking habits, height, weight,
as well as diabetes-specific variables such as diabetes-
related health complications and use of health services.
Finally, respondents were presented with eight diabetes-
specific HRQoL questions and an approved Norwegian
translation of the EQ-5D descriptive system. EQ-5D
responses were translated into EQ-5D index utilities
using the UK TTO tariff [18].
The questionnaire was mailed to a sample of members
of the Norwegian Diabetes Association. A large
proportion of the individuals with type 1 diabetes in
Norway are members of the NDA, while only a minority
of those with type 2 diabetes are members. After exclud-
ing individuals under the age of 18 years and those
without diabetes, such as health care workers and others
with an interest in diabetes, the NDA drew a random
sample of 1,000 members. Non-respondents were fol-
lowed up twice. The last follow up was accompanied by
al e t t e rf r o mt h eN D Ae x p l a ining the importance of
insight in diabetes and encouraging response.
Data analyses
For descriptive statistics, we used means, proportions
and standard deviations. Determinants of EQ-5D dimen-
sion values were analysed by logistic regression. For all 5
dimensions level 2 and 3 on the EQ-5D dimensions
were merged and thus dichotomized to “no problem” or
“some or extreme problem”. We performed separate
regressions for type 1 and type 2 diabetes.
The EQ-5D index was analysed with a linear OLS
regression model. The Breusch-Pagan test and plotting
residuals versus fitted values showed that heteroscedasti-
city was present both for type 1 and type 2 diabetes.
Therefore, we applied White’s robust variance
estimators.
T h ed a t aw e r ec o m p l e t ee x c e p tf o rt h ec o v a r i a t e s
“Fear of hypoglycaemia” (13% missing), “Limitations at
work” (23% missing) and “Limitations socially” (10%
missing). Missing values were therefore imputed with
regressions based on 15 independent variables (sex, age,
weight, height and 11 diabetes-related complications).
We used the impute function in STATA, which runs
regressions by simple best-subset linear regression, look-
ing at the pattern of missing values in the predictors.
We tested the covariates age and body mass index
first as dummy variables divided in quartiles and second
as continuous variables.
We chose covariates for the models based on input
from health care professionals and representatives from
academia. In the binary regressions the selected vari-
ables are considered plausible to be linked with the
dimension analysed. In addition to “Sex” and “age”,a l l
direct medical complications were included in all
dimensions except “Proteinuria”. We believe this covari-
a t ei sl i k e l yo n l yt or e m i n dt h ei n d i v i d u a l so fl u r k i n g
complications and should thus only impact the ANXI-
ETY/DEPRESSION dimension. The variable “Impaired
vision” is in our view not likely to directly cause pain or
discomfort and is not included in regression of the
PAIN/DISCOMFORT dimension. Emotional impact of
impaired vision should be captured in the ANXIETY/
DEPRESSION dimension.
In both the logistic binary and the linear regressions
full sets of the selected covariates were kept throughout
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nificant and non-significant impact on the covariates.
For the linear regression this would provide a full set of
results which may be used by other analysts in decision
analytic modelling.
All analyses were performed in STATA/SE 10.0 (Stata
Corp, College Station, TX, USA).
Results
Sample characteristics
Of the total 1,000 eligible individuals with diabetes, 17
were excluded because they had died (n = 4) or had
unknown address (n = 13). Two persons declined to
participate. In total 598 of those eligible returned the
questionnaire, of which 521 were complete and could be
used in further analysis (response rate 53%). Among
non-respondents, 51% were female compared with 47%
among respondents.
Among the 521 respondents, 165 reported having type
1 diabetes (53% female), and 356 type 2 diabetes (44%
female) (Table 1). Further descriptive statistics about
demographics, risk, factors for complications, medica-
tion and complications are shown in Table 1.
Health-related quality of life
In total 10% of those with type 1 diabetes had problems
with MOBILITY as judged from the EQ-5D, 3% with
SELF-CARE, 19% with USUAL ACTIVITIES, 34% with
PAIN/DISCOMFORT and 35% with ANXIETY/
DEPRESSION (Table 2). For Type 2 diabetes the num-
bers were 26%, 6%, 25%, 45% and 33%, respectively. The
mean EQ-5D index score was 0.83 (SD 0.24) in type 1
diabetes and 0.81 (SD 0.22) in type 2 (p =0 . 3 2 ) .T h e
proportion of type 2 diabetes patients with fear of hypo-
glycaemia was 50% among those on insulin and 26%
among the others.
For individuals without any reported complications,
the mean EQ-5D index scores were 0.90 for those with
type 1 diabetes and 0.85 for those with type 2 (Table 3).
The presence of one complication decreased values to
0.76 and 0.80, respectively. With two or more diabetes-
related complications the values were 0.55 and 0.64,
respectively.
Regression analyses
I nt h eb i n a r yl o g i s t i cr e g r e s s i o n so ft y p e1d i a b e t e so n
EQ-5D dimension responses (Table 4), ischemic heart
disease, foot ulcer, neuropathy, body mass index and
receiving help from others were statistically significant
determinants for reporting problems in the MOBILITY
dimension. None of the covariates had impact on the
SELF-CARE dimension. Disability pension and limita-
tions at work had an impact on the USUAL ACTIV-
ITIES dimension. Age, ischemic heart disease and
neuropathy had an impact on the PAIN/DISCOMFORT
dimension, and age, impaired vision, ischemic heart dis-
ease, neuropathy and fear of hypoglycaemia had an
impact on the ANXIETY/DEPRESSION dimension.
For type 2 diabetes (Table 5 ) ,a g e ,i m p a i r e dv i s i o n ,
stroke, neuropathy, body mass index and receiving help
from others were statistically significant determinants of
MOBILITY. Receiving help from others for SELF-CARE,
sex, stroke, disability pension, receiving help from others
Table 1 Characteristics of the respondents according to
diabetes type, number (%), unless otherwise specified
Type 1 Type 2
n 165 356
Demographics
Sex, female 87 (53) 157 (44)
Age, mean (SD) 47.0
(14.9)
64.0
(11.7)
Annual family income (1000 NOK), mean (SD) 666 (908) 713
(3051)
Complication risk factors
Diabetes duration (years), mean (SD) 22.1
(14.2)
10.0 (8.1)
Current smoking 47 (29) 62 (18)
Daily smoker 22 (14) 42 (12)
Occasional smoker 25 (15) 20 (6)
Previous smokers 86 (55) 200 (61)
Body mass index, kg/m
2 , mean (SD) 25.8 (4.8) 28.9 (5.1)
Medication
Number of oral antidiabetic agents
0 159 (96) 103 (29)
1 4 (2) 149 (42)
2 2 (1) 87 (24)
3 — 16 (5)
4 — 1 (0.3)
Insulin
Short-acting insulin 152 (92) 68 (19)
Long-acting insulin 103 (62) 98 (28)
Insulin glargine (Lantus) or insulin detemir
(Levemir)
51 (31) 11 (3)
Antihypertensives 52 (33) 217 (63)
Cholesterol lowering drug 45 (28) 205 (59)
Self-reported complications
Impaired vision 31 (19) 51 (14)
Myocardial infarction 4 (2) 38 (11)
Angina 10 (6) 27 (8)
Reduced kidney function (Proteinuria) 15 (9) 24 (7)
Kidney transplant 1 (1) 2 (1)
Foot ulcer 6 (4) 13 (4)
Amputation 2 (1) 1 (0.3)
Stroke 5 (3) 19 (5)
Neuropathy 12 (7) 17 (5)
Other 37 (22) 53 (15)
None 79 (47) 161 (45)
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ACTIVITIES. Ischemic heart disease, neuropathy and
hypoglycaemia had an impact on PAIN/DISCOMFORT.
Age, foot ulcers, number of hospital admissions during
the previous 6 months and fear of hypoglycaemia were
associated with ANXIETY/DEPRESSION scores.
In the linear regression of the EQ-5D index for type 1
diabetes, presence of ischemic heart disease had a nega-
tive impact (-0.181), along with stroke (-0.291), neuropa-
thy (-0.358), receiving disability pension (-0.111) and
social limitations (-0.107) (Table 6). For type 2 diabetes
the following conditions had a negative impact (Table
6): stroke (-0.135), neuropathy (-0.187), disability pen-
sion (-0.100), receiving help from others (-0.123), fear of
hypoglycaemia (-0.078) and limitations at work (-0.087).
For both diabetes types we tested for interactions, but
found none. We found no effect of age or body mass
index in the linear regressions whether age and BMI
were entered as one continuous variable or as dummy
variables.
Discussion
In this study, individuals with diabetes-related complica-
tions had reduced HRQoL, though the impact on
HRQoL was somewhat different for type 1 and type 2
diabetes. Stroke and neuropathy had a negative impact
on overall HRQoL in both types of diabetes, while
ischemic heart disease and social limitations had an
impact on those with type 1 diabetes, and fear of hypo-
glycaemia and limitations at work had an impact on
those with type 2 diabetics. Individuals with type 1 dia-
betes reported more problems than those with type 2 in
the PAIN/DISCOMFORT and ANXIETY/DEPRESSION
dimensions, while in the MOBILITY, SELF-CARE and
USUAL ACTIVITIES dimensions it was opposite. In
spite of the limited descriptive system of the EQ-5D, the
instrument still captures the impact of several diabetes
complications both with respect to each of the dimen-
sions and the EQ-5D index, and therefore individual
EQ-5D dimensions seem well suited to capture most
diabetes-related complications.
In a 2009 review of quality of life measurement in
adults with diabetes [19] the authors claim that the EQ-
5D measures quality of health and not quality of life
and that the EQ-5D lacks responsiveness for use in dia-
betes. The authors state that while the EQ-5D may cap-
ture differences due to diabetes related complications it
will not necessarily be able to capture differences across
treatment regimens. This is because the extent to which
a given treatment is considered flexible or convenient
will not affect quality of health but may affect aspects of
quality of life, such as social or working life. The
authors suggest using diabetes-specific instruments or a
different generic instrument more sensitive to differ-
ences between treatments. Our results show that while
both the individual dimensions of the EQ-5D and the
EQ-5D index are able to capture typical diabetes-related
complications, the subgroups without complications
reported surprisingly high EQ-5D index values. This
may indicate that the EQ-5D instrument was not able to
capture important non-health aspects of quality of life,
as claimed in the review [19]. Because the EQ-5D
instrument is not diabetes specific, lowered scores may
reflect the impact of unrelated comorbidity. A condition
specific instrument such as the ADDQoL may differenti-
ate better between diabetes related complications and
unrelated comorbidity [19].
In the present study, the finding that individuals with
type 1 diabetes reported better HRQoL than those with
type 2 can be explained by the younger age of the for-
mer group. The opposite was observed in subgroups
with complications, and it seems as if diabetic complica-
tions had more impact on HRQoL in type 1 diabetes
than type 2. A possible explanation is that complications
Table 2 Distribution of levels of perceived problem in
each of the dimensions of the EQ-5D descriptive system,
according to diabetes type
Type 1 (n = 165) Type 2 (n = 356)
Level of perceived problem, %
Dimension 1* 2* 3* 1* 2* 3*
Mobility 90 10 0 74 26 0
Self-care 97 3 0 94 6 0
Usual activities 81 18 1 74 24 1
Pain/discomfort 65 29 5 56 41 4
Anxiety/depression 65 32 3 67 30 3
* Level 1 implies no problem, 2 moderate problem, 3 severe problem
Table 3 Mean EQ-5D index utility values with and without diabetes-related complications
Type 1 diabetes Type 2 diabetes
Number of complications EQ-5D index 95% CI n EQ-5D index 95% CI n
0 0.90 0.88 - 0.93 111 0.85 0.82 - 0.87 241
1 0.76 0.66 - 0.86 35 0.80 0.75 - 0.85 68
≥ 2 0.55 0.37 - 0.73 19 0.64 0.56 - 0.71 47
Any complication 0.68 0.59 - 0.77 54 0.73 0.69 - 0.78 115
All patients 0.83 0.79 - 0.87 165 0.81 0.79 - 0.83 356
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ple with type 1 diabetes precisely because they are
younger, i.e. have less comorbidity and have not
adjusted to the idea of accepting lesser health. The dif-
ferences could also be explained by the fact that this
younger subgroup has responsibilities such as work and
family as well as relationship issues that are not found
in the older subgroup with type 2 diabetes.
In the UKPDS 37 study [20] individuals with type 2
diabetes and no complications had a mean EQ-5D index
value of 0.83, compared with 0.85 in our study. In type
2 diabetes with complications, our observed EQ-5D
index value (0.73) was equal to that of the UKPDS 37
study. Taking into account that patient characteristics
were similar in the UKPDS and our study, UK diabetes
studies may be transferable to the Norwegian setting. In
the UKPDS 37 study the EQ-5D detected significant dif-
ferences between people with and without
macrovascular complications, but not microvascular
complications or using different treatment regimens. In
our study the microvascular complication neuropathy
had impact on the individual EQ-5D dimensions and on
the EQ-5D index.
In another UK study [21] of individuals with type 2
diabetes, the change in utility associated with fear of
hypoglycaemia was relatively small compared with the
disutility for serious diabetic complications such as neu-
ropathy. Similarly, in our study fear of hypoglycaemia
caused a reduction in utility of 0.021 (type 1 diabetes)
and 0.078 (type 2), while the disutility of neuropathy
was larger with 0.358 (type 1 diabetes) and 0.187 (type 2
diabetes). We have no clear explanation why our results
indicate a lower impact on HRQoL of fear of hypogly-
caemia in individuals with type 1 diabetes than those
with type 2 diabetes. Fear of hypoglycaemia may not
affect HRQoL particularly (e.g. has little impact on pain
Table 4 Binary multivariate logistic regression of responses to the EQ-5D items in type 1 diabetics, odds ratios (95%
CI)
EQ-5D dimensions
Mobility Self-care Usual activities Pain/discomfort Anxiety/
depression
Sex (male = 0, female = 1) 0.63 (0.14 - 2.74) 0.25 (0.01 - 5.15) 0.67 (0.22 - 2.03) 0.45 (0.20 - 1.03) 1.12 (0.50 - 2.51)
Age (in 10 years) 1.33 (0.78 - 2.25) 1.37 (0.55 - 3.43) 0.93 (0.61 - 1.40) 1.36 (1.04 - 1.77)* 0.72 (0.55 - 0.94)*
Impaired vision (no = 0, yes = 1) 3.00 (0.53 - 16.85) 12.11 (0.49 -
297.88)
0.28 (0.07 - 1.15) ——— 4.60 (1.57 - 13.46)
**
Ischemic heart disease (no = 0, yes = 1) 11.72 (2.02 -
68.09)**
1.24 (0.05 -
31.42)
4.15 (0.73 - 23.64) 5.84 (1.29 - 26.40)* 6.82 (1.34 - 34.75)
*
Proteinuria (no = 0, yes = 1) ——— ——— ——— ——— 0.47 (0.09 - 2.47)
Foot Ulcer (no = 0, yes = 1) 13.33 (1.33 -
133.29)*
6.20 (0.17 -
221.73)
10.04 (0.80 -
126.22)
3.24 (0.47 - 22.43) 1.06 (0.16 - 6.96)
Stroke (no = 0, yes = 1) 0.47 (0.02 - 8.99) 17.37 (0.49 -
610.92)
1.24 (0.09 - 16.83) 10.66 (0.75 -
152.16)
1.14 (0.13 - 10.21)
Neuropathy (no = 0, yes = 1) 7.17 (1.22 - 42.03)
*
5.86 (0.41 -
83.43)
6.96 (1.45 - 33.44) 27.13 (3.13 -
235.07)**
4.61 (1.05 - 20.21)
*
Body mass index (kg/m
2 ) 1.15 (1.02 - 1.30)* ——— ——— ——— ———
Disability pension (no = 0, yes = 1) ——— ——— 4.64 (1.33 - 16.18)* ——— ———
Number of hospital admissions during previous 6
months
——— ——— ——— ——— 1.22 (0.58 - 2.53)
Receives help from others (no = 0, yes = 1) 10.04 (2.03 -
49.69)**
10.28 (0.61 -
173.34)
1.90 (0.50 - 7.22) ——— ———
Hypoglycaemia index# ——— ——— ——— 1.59 (0.87 - 2.89) 1.29 (0.71 - 2.33)
Fear of hypoglycaemia## (small = 0, large = 1) ——— ——— ——— ——— 3.98 (1.78 - 8.93)
**
Limitations at work## (small = 0, large = 1) ——— ——— 13.20 (3.38 -
51.53)***
——— ———
Limitations socially## (small = 0, large = 1) ——— ——— 1.87 (0.65 - 5.37) ——— ———
Log likelihood -28.08 -9.96 -51.46 -85.06 -85.30
* p < 0.05, **p < 0.01, ***p < 0.001
Cells with dotted line indicate that the variable was not included in the model.
# Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with the intake of for example fluids containing sugar, no
help from other required, level 2 = hypoglycaemia cured with the intake of for example fluids containing sugar, help from others required, level 3 =
hypoglycaemia with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital admission), then added with severity
weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max
## Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with decimals)
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quality of life (e.g. independence, spontaneity, ability to
work, enjoyment of leisure activities).
In a US review [22] of body weight and HRQoL in
type 2 diabetes, the authors found decreasing HRQoL
with increasing body weight in all included studies.
When adjusting for other explanatory variables, we
observed no significant impact of BMI on HRQoL.
A subgroup of individuals with unspecified type dia-
betes (n = 117) in a Swedish general population EQ-5D
study [23], also using the UK tariff, reported a higher
frequency of problems in all dimensions of the EQ-5D,
than in both diabetes categories in our study. Further,
the respondents in the study reported a lower mean
EQ-5D index (0.74) than we observed in both type 1
and type 2 diabetes.
Some limitations of the present study should be noted.
The respondents in the survey may not be representa-
tive of the population with diabetes. In particular, bias
may arise because sicker and older persons with type 2
diabetes did not respond to the survey. A large propor-
tion of individuals with type 1 diabetes in Norway
(about 20,000) are members of the NDA while only a
smaller proportion of the type 2 (about 100,000) are
members of this organization. Clearly, our study does
not capture HRQoL in undiagnosed diabetes patients. In
Table 5 Binary multivariate logistic regression of responses to the EQ-5D items in type 2 diabetics, odds ratios (95%
CI)
EQ-5D dimensions
Mobility Self-care Usual activities Pain/
discomfort
Anxiety/
depression
Sex
(male = 0, female = 1)
0.68 (0.38 - 1.21) 0.59 (0.23 - 1.54) 0.47 (0.25 - 0.88)* 0.82 (0.53 -
1.27)
0.91 (0.54 - 1.52)
Age
(in 10 years)
1.36 (1.03 - 1.80)* 0.83 (0.55 - 1.25) 1.34 (1.00 - 1.80) 1.03 (0.83 -
1.24)
0.78 (0.62 - 0.99)*
Impaired vision
(normal = 0, reduced = 1)
2.96 (1.44 - 6.10)** 2.29 (0.77 - 6.75) 0.89 (0.39 - 2.04) ——— 1.46 (0.71 - 3.01)
Ischemic heart disease (no = 0, yes = 1) 1.97 (0.91 - 4.25) 1.77 (0.54 - 5.86) 1.14 (0.48 - 2.71) 2.51 (1.27 -
4.97)**
1.15 (0.53 - 2.50)
Proteinuria (no = 0, yes = 1) ——— ——— ——— ——— 0.42 (0.14 - 1.29)
Foot Ulcer (no = 0, yes = 1) 0.32 (0.07 - 1.39) 0.73 (0.11 - 4.67) 2.11 (0.48 - 9.39) 2.18 (0.54 -
8.79)
7.00 (1.53 - 31.97)
*
Stroke (no = 0, yes = 1) 3.50 (1.13 - 10.82)* 1.45 (0.23 - 9.13) 4.48 (1.38 -
14.59)*
1.99 (0.72 -
5.54)
2.14 (0.69 - 6.62)
Neuropathy (no = 0, yes = 1) 12.07 (3.30 - 44.12)
***
2.74 (0.57 - 13.25) 3.08 (0.84 -
11.26)
Predicts
perfectly#
1.29 (0.40 - 4.16)
Body mass index (kg/m
2 ) 1.12 (1.05 - 1.19)
***
——— ——— ——— ———
Disability pension (no = 0, yes = 1) ——— ——— 2.38 (1.20 - 4.69)* ———
Number of hospital admissions during previous 6
months
——— ——— ——— ——— 1.87 (1.14 - 3.07)*
Receives help from others (no = 0, yes = 1) 5.85 (3.00 - 11.38)
***
6.95 (2.58 - 18.73)
***
4.67 (2.21 - 9.87)
***
——— ———
Hypoglycaemia index## ——— ——— ——— 1.68 (1.13 -
2.49)*
1.08 (0.70 - 1.68)
Fear of hypoglycaemia### (small = 0, large = 1) ——— ——— ——— ——— 5.76 (3.36 - 9.87)
***
Limitations at work### (small = 0, large = 1) ——— —— 6.95 (3.56 -13.56)
***
——— ———
Limitations socially### (small = 0, large = 1) ——— —— 1.33 (0.67 - 2.62) ——— ———
Log likelihood -156.08 -66.13 -136.85 -232.10 -187.32
* p < 0.05, **p < 0.01, ***p < 0.001
# All patients reporting neuropathy also reports having problems in the PAIN/DISCOMFORT dimension of the EQ-5D.
Cells with dotted line indicate that the variable was not included in the model.
## Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with the intake of for example fluids containing sugar, no
help from other required, level 2 = hypoglycaemia cured with the intake of for example fluids containing sugar, help from others required, level 3 =
hypoglycaemia with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital admission), then added with severity
weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max
### Self reported on a scale from 1 to 5 (1 = not at all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with
decimals)
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Page 6 of 8line with other patient surveys, we had 47% non-
response. We have no information on non-respondents
except for sex (based on non-respondents first names),
and here there was little difference between responders
and non-responders.
It is important to be aware that because the EQ-5D
instrument is no diabetes specific it may reflect pro-
blems related to other conditions. Our study was per-
formed at one point in time, and fluctuations are likely
to occur if HRQoL was measured at multiple points in
time. The observed associations are not necessarily cau-
sal. Further they are limited by the lack of serial obser-
vations. Furthermore, the limited sample size, especially
for type 1 diabetes may limit the power for some of the
comparisons of presence or absence of complications.
Note that despite the index score being a function of
the score in the dimensions a significant impact on lin-
ear regression of the index does not necessarily imply a
significant impact on one or more of the dimensions.
T h i si st h ec a s ef o rt h ec o v a r i a t e“stroke” which is sig-
nificant in both types of diabetes in the linear regression
by not significant in any of the dimensions in the type 1
diabetes group.
Lacking a Norwegian EQ-5D tariff we used the UK
tariff, based on TTO [18]. This tariff is probably the
most commonly used EQ-5D tariff globally, and quite
similar to the Danish one [24]. Also, one small
Norwegian study indicates that UK and Norwegian
values are quite similar [25].
Conclusions
In this sample of people with diabetes, the individual
EQ-5D dimensions were able to capture diabetes-related
complications. The results show that such complications
may have an impact on many dimensions of health-
related quality of life, and the impact may be substantial.
The strongest determinants of reduced HRQoL, as
assessed with the EQ-5D index, were ischemic heart dis-
ease, stroke and neuropathy. The complexity of the dis-
ease means that several dimensions need to be
considered when priorities are set for diabetes
interventions.
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Table 6 Linear multivariate regression of EQ-5D index, according to diabetes type
Type 1 Type 2
N 165 356
Coefficient (95% CI) P > |t| Coefficient (95% CI) P > |t|
Constant 1.092 (0.921 to 1.263) <0.001 0.990 (0.787 to 1.193) <0.001
Sex (male = 0, female = 1) 0.041 (-0.023 to 0.105) 0.210 0.024 (-0.016 to 0.064) 0.240
Age (in 10 years) -0.003 (-0.022 to 0.016) 0.749 0.0004 (-0.017 to 0.017) 0.967
Impaired vision (no = 0, yes = 1) -0.063 (-0.169 to 0.044) 0.245 -0.012 (-0.074 to 0.051) 0.711
Ischemic heart disease (no = 0, yes = 1) -0.181 (-0.331 to -0.031) 0.019 -0.037 (-0.103 to 0.030) 0.276
Proteinuria (no = 0, yes = 1) 0.089 (-0.036 to 0.215) 0.161 0.043 (-0.019 to 0.106) 0.174
Foot Ulcer (no = 0, yes = 1) -0.083 (-0.271 to 0.105) 0.383 -0.016 (-0.134 to 0.101) 0.783
Stroke (no = 0, yes = 1) -0.291 (-0.475 to -0.108) 0.002 -0.135 (-0.247 to -0.023) 0.018
Neuropathy (no = 0, yes = 1) -0.358 (-0.535 to -0.180) <0.001 -0.187 (-0.316 to -0.057) 0.005
Body mass index (kg/m
2 ) -0.004 (-0.008 to 0.001) 0.123 -0.002 (-0.007 to 0.002) 0.307
Disability pension (no = 0, yes = 1) -0.111 (-0.191 to -0.030) 0.008 -0.100 (-0.153 to -0.046) <0.001
Number of hospital admissions during previous 6 months 0.003 (-0.042 to 0.049) 0.880 -0.028 (-0.076 to 0.020) 0.255
Receives help from others (no = 0, yes = 1) -0.090 (-0.217 to 0.037) 0.166 -0.123 (-0.185 to -0.060) <0.001
Hypoglycaemia index# -0.023 (-0.071 to 0.025) 0.337 -0.004 (-0.039 to 0.032) 0.839
Fear of hypoglycaemia## (small = 0, large = 1) -0.021 (-0.073 to 0.031) 0.432 -0.078 (-0.129 to -0.028) 0.003
Limitations at work## (small = 0, large = 1) -0.023 (-0.089 to 0.043) 0.494 -0.087 (-0.148 to -0.025) 0.006
Limitations socially## (small = 0, large = 1) -0.107 (-0.188 to -0.026) 0.010 -0.002 (-0.049 to 0.046) 0.944
# Self reported episodes of hypoglycaemia, with 4 levels of severity (level 1 = hypoglycaemia cured with the intake of for example fluids containing sugar, no
help from other required, level 2 = hypoglycaemia cured with the intake of for example fluids containing sugar, help from others required, level 3 =
hypoglycaemia with help from doctor required (no hospital admission), level 4 = hypoglycaemia resulting in hospital admission), then added with severity
weights (level 1 × 1, level 2 × 2, level 3 × 3, level 4 × 4) and finally divided in 3 groups 0, 1-11 and 12 to max ## Self reported on a scale from 1 to 5 (1 = not at
all, 5 = very much), recoded to 2 levels (> and < than 2.5 due to imputed values having values with decimals)
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